Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 7/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861393 | 0.75 | NOX4 (0.43) | BRD4CYP3A4 | |
| SCHEMBL27355627 | 0.73 | KEAP1 (0.43) | CYP1A2CYP3A4KMT2A | |
| SCHEMBL27355422 | 0.73 | KEAP1 (0.43) | CYP1A2CYP3A4KMT2A | |
| SCHEMBL1860045 | 0.72 | NPSR1 (0.40) | PTGS2PDE4APDE4CPDE4DKMT2A | |
| SCHEMBL1773119 | 0.72 | CXCR2 (0.46) | PDE4APDE4CPDE4DCYP1A2CYP3A4 | |
| SCHEMBL24644926 | 0.69 | TP53 (0.42) | BRD4CYP1A2CYP3A4KMT2A | |
| SCHEMBL8896304 | 0.69 | CYP1A2 (0.43) | CYP1A2KMT2A | |
| SCHEMBL14242958 | 0.69 | SLC6A3 (0.56) | PDE4APDE4CPDE4DCYP1A2CYP3A4 | |
| SCHEMBL28787425 | 0.68 | CXCR2 (0.51) | PDE4APDE4CPDE4DCYP1A2CYP3A4 | |
| SCHEMBL17292461 | 0.67 | MEN1 (0.41) | CYP3A4KMT2AADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231653-B1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2013-04-03 | — | — | EP | disclosed |
| US-8299065-B2 | Antibacterial condensed thiazoles | BIOTA EUROPE LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2231653-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | Biota Europe Ltd (GB) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074812-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | PROLYSIS LTD (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | NEK6, NEK1, TXK | PTGS2 3527/4885BRD4 478/4885PDE4A 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.